Data on the efficiency of specific antimumps immunoglobulins in the prevention of mumps and of its complications.
Administration of specific antimumps immunoglobulins(Ig) to mumps contacts in various children communities conferred protection only when performed early after the outbreak of the epidemic and if the proportion of previous mumps cases did not surpass 8% of the total number of children. Application of specific Ig to mumps patients within the first 5 days after onset prevented the appearance of secondary determinations and/or complications and reduced the duration of the disease and of the hospitalization period. The efficiency of standard gamma-globulins was very limited.
D002648:Child; D002675:Child, Preschool; D006801:Humans; D007136:Immunoglobulins / Q000008:administration & dosage / Q000627:therapeutic use*; D007273:Injections, Intramuscular; D009107:Mumps / Q000453:epidemiology / Q000517:prevention & control*; D012383:Romania; D005719:gamma-Globulins / Q000627:therapeutic use*
D007136:Immunoglobulins; D005719:gamma-Globulins